Aldesleukin

March 25, 2025 -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), ”), a leader in RNA-based therapeutics, announced today the successful completion of a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101,an antisense therapeutic targeting Transforming Growth Factor Beta 2 (TGFβ2), with checkpoint inhibitors (“CKIs”) and recombinant IL-2 (aldesleukin) (“IL-2”). The announcement coincides with a presentation delivered by Vuong Trieu, Ph.D., Chairman & CEO of Oncotelic, at the 5th Symposium on World Cancer Research (SWCR) 2025. In his talk, titled “Transforming Growth Factor Beta 2 in Aging, Cancer, Lupus, and Immuno-Oncology: A Convergence of Disease Pathways and Therapeutic Potential,” Dr. Trieu described the central role of TGFβ2 in immune suppression across multiple diseases, and outlined the ongoing development of OT-101 in pancreatic cancer (Phase 3 STOP-PC study), gliomas, and combination regimens with immunotherapies. The Phase 1 trial (ClinicalTrials.gov ID: NCT04862767) investigated the safety and tolerability of OT-101 in combination with recombinant IL-2 in patients with advanced or metastatic solid tumors. The combination showed a tolerable safety profile at the planned dosing schedule, with no unexpected safety signals identified. Based on the favorable safety data, Oncotelic plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers. TGFβ2’s Central Role in Cancer and Beyond: Dr. Trieu presented evidence that TGFβ2 is a critical driver of immunosuppression, fueling tumor progression by promoting an M2-like macrophage phenotype and blunting antitumor immunity. OT-101’s Clinical Progress and Versatility: In pancreatic ductal adenocarcinoma (PDAC), OT-101 is currently in a Phase 3 clinical trial (the STOP-PC study) combined with mFOLFIRINOX. OT-101 has shown encouraging activity in gliomas, where high intratumoral TGFβ2 expression correlates with poor prognosis. Combination regimens with CKIs and IL-2 address multiple pathways of immune evasion, potentially amplifying therapeutic benefits. Next Studies Targeting TGF β2 and Beyond: With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung cancer, melanoma, and colorectal cancer. Next wave of clinical trials aiming to knock down TGF β 2 (e.g., with OT-101) paired with intervention with a complementary therapy, checkpoint blockade, IL-2, interferon-based regimens, or standard-of-care chemo, depending on the tumor indication “We are thrilled to announce the completion of our Phase 1 study evaluating OT-101 with IL-2, a key milestone that sets the stage for next-generation immunotherapy combinations,” said Dr. Vuong Trieu, Chairman & CEO of Oncotelic. Our findings reinforce that OT-101’s specific inhibition of TGFβ2 can significantly enhance the immune response, and we are eager to test these synergies with checkpoint inhibitors and IL-2 to maximize therapeutic potential for patients with hard-to-treat cancers.” The presentation, along with a chatbot powered by PDAOAI, can be accessed on our new PDAOAI public Discord: https://discord.gg/jz6Q7G2SBQ. Our PDAOAI Discord server allows members of the public to view and download the presentation. In addition, by using “/query”, they can utilize our proprietary chatbot technology to ask questions related to the presentation. We highly recommend joining Discord. If you need any help, members of the PDAOAI team can assist. In addition, you can use “/help”. We intend to use this server for our PDAOAI platform. For those who are interested in joining our investor Discord, can do so here: https://discord.gg/hMDV397832 "We are excited to bring PDAOAI to the public and are excited for the user feedback. This presentation is a beginning to bringing our AI technology to the masses and not just our internal team,” said Scott Myers, Product Manager. Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (“AML” through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our 2023 Annual Report on form 10-K filed with the SEC on April 12, 2024. The content above comes from the network. if any infringement, please contact us to modify.

Plus, news about Relmada Therapeutics and Mural Oncology: Cassava Sciences finally stops work on Alzheimer’s drug: After a Phase 3 study of simufilam failed in November, Cassava said it was discontinuing a second Phase 3 trial. On Tuesday, the company said that trial failed, too, and it would stop work on simufilam in Alzheimer’s by the end of June. The drug did not meet primary, secondary or exploratory biomarker endpoints. “These results were unambiguous,” CEO Rick Barry said in a press statement. The SEC last year accused the drug’s co-developer Hoau-Yan Wang, a CUNY School of Medicine professor, of manipulating clinical trial results. Former CEO Remi Barbier and SVP of neuroscience Lindsay Burns paid more than $40 million to settle charges they made misleading statements about the Phase 2 studies. They allegedly told investors that the drug had significant therapeutic benefits when it did not. The company then continued studying the treatment. Cassava said Tuesday that it started preclinical studies of simufilam for epilepsy in people with tuberous sclerosis complex. Its stock $SAVA was down about 21% on Tuesday morning. — Lei Lei Wu Alumis inks deal in Japan: The California immunology biotech will get $40 million in upfront and near-term payments from Kaken Pharmaceutical as part of a licensing deal for rights to its oral TYK2 inhibitor in Japan. The Tokyo-based drugmaker also promised about $140 million in biobucks as part of the licensing deal for Alumis’ ESK-001 in dermatology indications. Alumis shares $ALMS were up about 22% on Tuesday morning. It is currently working on a merger with Acelyrin . — Kyle LaHucik Relmada Therapeutics’ bladder cancer deal: The Florida biotech will pay $3.5 million upfront and issue 3 million, or 10%, of its shares to Trigone Pharma for worldwide rights to an experimental bladder cancer drug. Called NDV-01, the drug is a sustained-release and intravesical formulation of gemcitabine and docetaxel. Relmada will take over development and other work for NDV-01 once an ongoing Phase 2 wraps up. Relmada gets rights to all regions except India, Israel and South Africa. Trigone could receive another $200 million in milestone payments and 3% royalties on net sales. The move comes a few months after Relmada’s depression drug failed another Phase 3 trial. — Kyle LaHucik Mural Oncology to stop a Phase 3 study in ovarian cancer: The biotech said an interim survival analysis showed that its IL-2 drug, called nemvaleukin alfa, plus Merck’s Keytruda was unlikely to succeed versus chemotherapy. Mural’s stock $MURA fell 60% on Tuesday morning. — Lei Lei Wu